Analysis of Reportable Segments
Abbott Laboratories operates in 4 segments: Established Pharmaceutical Products; Nutritional Products; Diagnostic Products; and Medical Devices.
Segment Profit Margin
Abbott Laboratories, profit margin by reportable segment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Established Pharmaceutical Products | 23.74% | 23.81% | 21.36% | 18.84% | 18.45% |
| Nutritional Products | 17.89% | 16.35% | 9.47% | 21.26% | 22.90% |
| Diagnostic Products | 22.19% | 24.36% | 40.20% | 39.99% | 34.47% |
| Medical Devices | 32.41% | 31.42% | 30.02% | 31.42% | 25.77% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | Established Pharmaceutical Products | Established Pharmaceutical Products segment profit margin ratio improved from 2022 to 2023 but then slightly deteriorated from 2023 to 2024. |
| Nutritional Products | Nutritional Products segment profit margin ratio improved from 2022 to 2023 and from 2023 to 2024. | |
| Diagnostic Products | Diagnostic Products segment profit margin ratio deteriorated from 2022 to 2023 and from 2023 to 2024. | |
| Medical Devices | Medical Devices segment profit margin ratio improved from 2022 to 2023 and from 2023 to 2024. |
Segment Profit Margin: Established Pharmaceutical Products
Abbott Laboratories; Established Pharmaceutical Products; segment profit margin calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating earnings | 1,233) | 1,206) | 1,049) | 889) | 794) |
| Net sales | 5,194) | 5,066) | 4,912) | 4,718) | 4,303) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | 23.74% | 23.81% | 21.36% | 18.84% | 18.45% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment profit margin = 100 × Operating earnings ÷ Net sales
= 100 × 1,233 ÷ 5,194 = 23.74%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | Established Pharmaceutical Products | Established Pharmaceutical Products segment profit margin ratio improved from 2022 to 2023 but then slightly deteriorated from 2023 to 2024. |
Segment Profit Margin: Nutritional Products
Abbott Laboratories; Nutritional Products; segment profit margin calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating earnings | 1,505) | 1,333) | 706) | 1,763) | 1,751) |
| Net sales | 8,413) | 8,154) | 7,459) | 8,294) | 7,647) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | 17.89% | 16.35% | 9.47% | 21.26% | 22.90% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment profit margin = 100 × Operating earnings ÷ Net sales
= 100 × 1,505 ÷ 8,413 = 17.89%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | Nutritional Products | Nutritional Products segment profit margin ratio improved from 2022 to 2023 and from 2023 to 2024. |
Segment Profit Margin: Diagnostic Products
Abbott Laboratories; Diagnostic Products; segment profit margin calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating earnings | 2,073) | 2,433) | 6,667) | 6,256) | 3,725) |
| Net sales | 9,341) | 9,988) | 16,584) | 15,644) | 10,805) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | 22.19% | 24.36% | 40.20% | 39.99% | 34.47% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment profit margin = 100 × Operating earnings ÷ Net sales
= 100 × 2,073 ÷ 9,341 = 22.19%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | Diagnostic Products | Diagnostic Products segment profit margin ratio deteriorated from 2022 to 2023 and from 2023 to 2024. |
Segment Profit Margin: Medical Devices
Abbott Laboratories; Medical Devices; segment profit margin calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating earnings | 6,153) | 5,306) | 4,409) | 4,514) | 3,038) |
| Net sales | 18,986) | 16,887) | 14,687) | 14,367) | 11,787) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | 32.41% | 31.42% | 30.02% | 31.42% | 25.77% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment profit margin = 100 × Operating earnings ÷ Net sales
= 100 × 6,153 ÷ 18,986 = 32.41%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | Medical Devices | Medical Devices segment profit margin ratio improved from 2022 to 2023 and from 2023 to 2024. |
Segment Return on Assets (Segment ROA)
Abbott Laboratories, ROA by reportable segment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Established Pharmaceutical Products | 39.94% | 38.68% | 36.39% | 31.88% | 27.49% |
| Nutritional Products | 34.17% | 31.22% | 19.48% | 51.47% | 50.35% |
| Diagnostic Products | 27.00% | 31.32% | 83.49% | 81.26% | 48.40% |
| Medical Devices | 64.96% | 58.77% | 56.21% | 62.17% | 44.07% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment ROA | Established Pharmaceutical Products | Established Pharmaceutical Products segment ROA improved from 2022 to 2023 and from 2023 to 2024. |
| Nutritional Products | Nutritional Products segment ROA improved from 2022 to 2023 and from 2023 to 2024. | |
| Diagnostic Products | Diagnostic Products segment ROA deteriorated from 2022 to 2023 and from 2023 to 2024. | |
| Medical Devices | Medical Devices segment ROA improved from 2022 to 2023 and from 2023 to 2024. |
Segment ROA: Established Pharmaceutical Products
Abbott Laboratories; Established Pharmaceutical Products; segment ROA calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating earnings | 1,233) | 1,206) | 1,049) | 889) | 794) |
| Total assets | 3,087) | 3,118) | 2,883) | 2,789) | 2,888) |
| Segment Profitability Ratio | |||||
| Segment ROA1 | 39.94% | 38.68% | 36.39% | 31.88% | 27.49% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment ROA = 100 × Operating earnings ÷ Total assets
= 100 × 1,233 ÷ 3,087 = 39.94%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment ROA | Established Pharmaceutical Products | Established Pharmaceutical Products segment ROA improved from 2022 to 2023 and from 2023 to 2024. |
Segment ROA: Nutritional Products
Abbott Laboratories; Nutritional Products; segment ROA calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating earnings | 1,505) | 1,333) | 706) | 1,763) | 1,751) |
| Total assets | 4,404) | 4,270) | 3,625) | 3,425) | 3,478) |
| Segment Profitability Ratio | |||||
| Segment ROA1 | 34.17% | 31.22% | 19.48% | 51.47% | 50.35% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment ROA = 100 × Operating earnings ÷ Total assets
= 100 × 1,505 ÷ 4,404 = 34.17%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment ROA | Nutritional Products | Nutritional Products segment ROA improved from 2022 to 2023 and from 2023 to 2024. |
Segment ROA: Diagnostic Products
Abbott Laboratories; Diagnostic Products; segment ROA calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating earnings | 2,073) | 2,433) | 6,667) | 6,256) | 3,725) |
| Total assets | 7,678) | 7,767) | 7,985) | 7,699) | 7,696) |
| Segment Profitability Ratio | |||||
| Segment ROA1 | 27.00% | 31.32% | 83.49% | 81.26% | 48.40% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment ROA = 100 × Operating earnings ÷ Total assets
= 100 × 2,073 ÷ 7,678 = 27.00%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment ROA | Diagnostic Products | Diagnostic Products segment ROA deteriorated from 2022 to 2023 and from 2023 to 2024. |
Segment ROA: Medical Devices
Abbott Laboratories; Medical Devices; segment ROA calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating earnings | 6,153) | 5,306) | 4,409) | 4,514) | 3,038) |
| Total assets | 9,472) | 9,029) | 7,844) | 7,261) | 6,893) |
| Segment Profitability Ratio | |||||
| Segment ROA1 | 64.96% | 58.77% | 56.21% | 62.17% | 44.07% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment ROA = 100 × Operating earnings ÷ Total assets
= 100 × 6,153 ÷ 9,472 = 64.96%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment ROA | Medical Devices | Medical Devices segment ROA improved from 2022 to 2023 and from 2023 to 2024. |
Segment Asset Turnover
Abbott Laboratories, asset turnover by reportable segment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Established Pharmaceutical Products | 1.68 | 1.62 | 1.70 | 1.69 | 1.49 |
| Nutritional Products | 1.91 | 1.91 | 2.06 | 2.42 | 2.20 |
| Diagnostic Products | 1.22 | 1.29 | 2.08 | 2.03 | 1.40 |
| Medical Devices | 2.00 | 1.87 | 1.87 | 1.98 | 1.71 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
| Segment activity ratio | Reportable segment | The company |
|---|---|---|
| Segment asset turnover | Established Pharmaceutical Products | Established Pharmaceutical Products segment asset turnover ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 not reaching 2022 level. |
| Nutritional Products | Nutritional Products segment asset turnover ratio deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024. | |
| Diagnostic Products | Diagnostic Products segment asset turnover ratio deteriorated from 2022 to 2023 and from 2023 to 2024. | |
| Medical Devices | Medical Devices segment asset turnover ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level. |
Segment Asset Turnover: Established Pharmaceutical Products
Abbott Laboratories; Established Pharmaceutical Products; segment asset turnover calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Net sales | 5,194) | 5,066) | 4,912) | 4,718) | 4,303) |
| Total assets | 3,087) | 3,118) | 2,883) | 2,789) | 2,888) |
| Segment Activity Ratio | |||||
| Segment asset turnover1 | 1.68 | 1.62 | 1.70 | 1.69 | 1.49 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment asset turnover = Net sales ÷ Total assets
= 5,194 ÷ 3,087 = 1.68
| Segment activity ratio | Reportable segment | The company |
|---|---|---|
| Segment asset turnover | Established Pharmaceutical Products | Established Pharmaceutical Products segment asset turnover ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 not reaching 2022 level. |
Segment Asset Turnover: Nutritional Products
Abbott Laboratories; Nutritional Products; segment asset turnover calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Net sales | 8,413) | 8,154) | 7,459) | 8,294) | 7,647) |
| Total assets | 4,404) | 4,270) | 3,625) | 3,425) | 3,478) |
| Segment Activity Ratio | |||||
| Segment asset turnover1 | 1.91 | 1.91 | 2.06 | 2.42 | 2.20 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment asset turnover = Net sales ÷ Total assets
= 8,413 ÷ 4,404 = 1.91
| Segment activity ratio | Reportable segment | The company |
|---|---|---|
| Segment asset turnover | Nutritional Products | Nutritional Products segment asset turnover ratio deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024. |
Segment Asset Turnover: Diagnostic Products
Abbott Laboratories; Diagnostic Products; segment asset turnover calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Net sales | 9,341) | 9,988) | 16,584) | 15,644) | 10,805) |
| Total assets | 7,678) | 7,767) | 7,985) | 7,699) | 7,696) |
| Segment Activity Ratio | |||||
| Segment asset turnover1 | 1.22 | 1.29 | 2.08 | 2.03 | 1.40 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment asset turnover = Net sales ÷ Total assets
= 9,341 ÷ 7,678 = 1.22
| Segment activity ratio | Reportable segment | The company |
|---|---|---|
| Segment asset turnover | Diagnostic Products | Diagnostic Products segment asset turnover ratio deteriorated from 2022 to 2023 and from 2023 to 2024. |
Segment Asset Turnover: Medical Devices
Abbott Laboratories; Medical Devices; segment asset turnover calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Net sales | 18,986) | 16,887) | 14,687) | 14,367) | 11,787) |
| Total assets | 9,472) | 9,029) | 7,844) | 7,261) | 6,893) |
| Segment Activity Ratio | |||||
| Segment asset turnover1 | 2.00 | 1.87 | 1.87 | 1.98 | 1.71 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment asset turnover = Net sales ÷ Total assets
= 18,986 ÷ 9,472 = 2.00
| Segment activity ratio | Reportable segment | The company |
|---|---|---|
| Segment asset turnover | Medical Devices | Medical Devices segment asset turnover ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level. |
Segment Capital Expenditures to Depreciation
Abbott Laboratories, capital expenditures to depreciation by reportable segment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Established Pharmaceutical Products | 1.91 | 1.78 | 1.80 | 1.80 | 1.24 |
| Nutritional Products | 2.40 | 2.95 | 1.62 | 1.15 | 1.41 |
| Diagnostic Products | 1.45 | 1.50 | 1.68 | 1.29 | 2.59 |
| Medical Devices | 1.84 | 1.92 | 1.08 | 1.22 | 1.43 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
| Segment financial ratio | Reportable segment | The company |
|---|---|---|
| Segment capital expenditures to depreciation | Established Pharmaceutical Products | Established Pharmaceutical Products segment capital expenditures to depreciation ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level. |
| Nutritional Products | Nutritional Products segment capital expenditures to depreciation ratio improved from 2022 to 2023 but then slightly deteriorated from 2023 to 2024. | |
| Diagnostic Products | Diagnostic Products segment capital expenditures to depreciation ratio deteriorated from 2022 to 2023 and from 2023 to 2024. | |
| Medical Devices | Medical Devices segment capital expenditures to depreciation ratio improved from 2022 to 2023 but then slightly deteriorated from 2023 to 2024. |
Segment Capital Expenditures to Depreciation: Established Pharmaceutical Products
Abbott Laboratories; Established Pharmaceutical Products; segment capital expenditures to depreciation calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Additions to property and equipment | 183) | 185) | 175) | 169) | 109) |
| Depreciation | 96) | 104) | 97) | 94) | 88) |
| Segment Financial Ratio | |||||
| Segment capital expenditures to depreciation1 | 1.91 | 1.78 | 1.80 | 1.80 | 1.24 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment capital expenditures to depreciation = Additions to property and equipment ÷ Depreciation
= 183 ÷ 96 = 1.91
| Segment financial ratio | Reportable segment | The company |
|---|---|---|
| Segment capital expenditures to depreciation | Established Pharmaceutical Products | Established Pharmaceutical Products segment capital expenditures to depreciation ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level. |
Segment Capital Expenditures to Depreciation: Nutritional Products
Abbott Laboratories; Nutritional Products; segment capital expenditures to depreciation calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Additions to property and equipment | 382) | 457) | 251) | 174) | 201) |
| Depreciation | 159) | 155) | 155) | 151) | 143) |
| Segment Financial Ratio | |||||
| Segment capital expenditures to depreciation1 | 2.40 | 2.95 | 1.62 | 1.15 | 1.41 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment capital expenditures to depreciation = Additions to property and equipment ÷ Depreciation
= 382 ÷ 159 = 2.40
| Segment financial ratio | Reportable segment | The company |
|---|---|---|
| Segment capital expenditures to depreciation | Nutritional Products | Nutritional Products segment capital expenditures to depreciation ratio improved from 2022 to 2023 but then slightly deteriorated from 2023 to 2024. |
Segment Capital Expenditures to Depreciation: Diagnostic Products
Abbott Laboratories; Diagnostic Products; segment capital expenditures to depreciation calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Additions to property and equipment | 758) | 750) | 832) | 980) | 1,263) |
| Depreciation | 521) | 499) | 494) | 760) | 488) |
| Segment Financial Ratio | |||||
| Segment capital expenditures to depreciation1 | 1.45 | 1.50 | 1.68 | 1.29 | 2.59 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment capital expenditures to depreciation = Additions to property and equipment ÷ Depreciation
= 758 ÷ 521 = 1.45
| Segment financial ratio | Reportable segment | The company |
|---|---|---|
| Segment capital expenditures to depreciation | Diagnostic Products | Diagnostic Products segment capital expenditures to depreciation ratio deteriorated from 2022 to 2023 and from 2023 to 2024. |
Segment Capital Expenditures to Depreciation: Medical Devices
Abbott Laboratories; Medical Devices; segment capital expenditures to depreciation calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Additions to property and equipment | 630) | 604) | 335) | 348) | 402) |
| Depreciation | 343) | 315) | 311) | 285) | 281) |
| Segment Financial Ratio | |||||
| Segment capital expenditures to depreciation1 | 1.84 | 1.92 | 1.08 | 1.22 | 1.43 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment capital expenditures to depreciation = Additions to property and equipment ÷ Depreciation
= 630 ÷ 343 = 1.84
| Segment financial ratio | Reportable segment | The company |
|---|---|---|
| Segment capital expenditures to depreciation | Medical Devices | Medical Devices segment capital expenditures to depreciation ratio improved from 2022 to 2023 but then slightly deteriorated from 2023 to 2024. |
Net sales
Abbott Laboratories, net sales by reportable segment
US$ in millions
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Established Pharmaceutical Products | 5,194) | 5,066) | 4,912) | 4,718) | 4,303) |
| Nutritional Products | 8,413) | 8,154) | 7,459) | 8,294) | 7,647) |
| Diagnostic Products | 9,341) | 9,988) | 16,584) | 15,644) | 10,805) |
| Medical Devices | 18,986) | 16,887) | 14,687) | 14,367) | 11,787) |
| Total reportable segments | 41,934) | 40,095) | 43,642) | 43,023) | 34,542) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
Operating earnings
Abbott Laboratories, operating earnings by reportable segment
US$ in millions
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Established Pharmaceutical Products | 1,233) | 1,206) | 1,049) | 889) | 794) |
| Nutritional Products | 1,505) | 1,333) | 706) | 1,763) | 1,751) |
| Diagnostic Products | 2,073) | 2,433) | 6,667) | 6,256) | 3,725) |
| Medical Devices | 6,153) | 5,306) | 4,409) | 4,514) | 3,038) |
| Total reportable segments | 10,964) | 10,278) | 12,831) | 13,422) | 9,308) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
Depreciation
Abbott Laboratories, depreciation by reportable segment
US$ in millions
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Established Pharmaceutical Products | 96) | 104) | 97) | 94) | 88) |
| Nutritional Products | 159) | 155) | 155) | 151) | 143) |
| Diagnostic Products | 521) | 499) | 494) | 760) | 488) |
| Medical Devices | 343) | 315) | 311) | 285) | 281) |
| Total reportable segments | 1,119) | 1,073) | 1,057) | 1,290) | 1,000) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
Additions to property and equipment
Abbott Laboratories, additions to property and equipment by reportable segment
US$ in millions
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Established Pharmaceutical Products | 183) | 185) | 175) | 169) | 109) |
| Nutritional Products | 382) | 457) | 251) | 174) | 201) |
| Diagnostic Products | 758) | 750) | 832) | 980) | 1,263) |
| Medical Devices | 630) | 604) | 335) | 348) | 402) |
| Total reportable segments | 1,953) | 1,996) | 1,593) | 1,671) | 1,975) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
Total assets
Abbott Laboratories, total assets by reportable segment
US$ in millions
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Established Pharmaceutical Products | 3,087) | 3,118) | 2,883) | 2,789) | 2,888) |
| Nutritional Products | 4,404) | 4,270) | 3,625) | 3,425) | 3,478) |
| Diagnostic Products | 7,678) | 7,767) | 7,985) | 7,699) | 7,696) |
| Medical Devices | 9,472) | 9,029) | 7,844) | 7,261) | 6,893) |
| Total reportable segments | 24,641) | 24,184) | 22,337) | 21,174) | 20,955) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).